Rocket Pharmaceuticals Statistics
Share Statistics
Rocket Pharmaceuticals has 107.74M
shares outstanding. The number of shares has increased by 17.46%
in one year.
| Shares Outstanding | 107.74M |
| Shares Change (YoY) | 17.46% |
| Shares Change (QoQ) | 0.28% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,187 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 12.26M, so 11.38% of the outstanding
shares have been sold short.
| Short Interest | 12.26M |
| Short % of Shares Out | 11.38% |
| Short % of Float | 22.18% |
| Short Ratio (days to cover) | 4.61 |
Valuation Ratios
The PE ratio is -4.61 and the forward
PE ratio is -4.37.
Rocket Pharmaceuticals's PEG ratio is
0.71.
| PE Ratio | -4.61 |
| Forward PE | -4.37 |
| PS Ratio | 0 |
| Forward PS | 0.9 |
| PB Ratio | 2.57 |
| P/FCF Ratio | -5.53 |
| PEG Ratio | 0.71 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Rocket Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.3,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.3 |
| Quick Ratio | 9.3 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.09 |
| Debt / FCF | -0.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-865,371.24 |
| Employee Count | 299 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -71.69% in the
last 52 weeks. The beta is 1.02, so Rocket Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -71.69% |
| 50-Day Moving Average | 7.27 |
| 200-Day Moving Average | 13.3 |
| Relative Strength Index (RSI) | 45.17 |
| Average Volume (20 Days) | 2,930,086 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -273.2M |
| Net Income | -258.75M |
| EBITDA | -273.2M |
| EBIT | -260.63M |
| Earnings Per Share (EPS) | -2.73 |
Full Income StatementBalance Sheet
The company has 163.63M in cash and 25.5M in
debt, giving a net cash position of 138.14M.
| Cash & Cash Equivalents | 163.63M |
| Total Debt | 25.5M |
| Net Cash | 138.14M |
| Retained Earnings | -1.22B |
| Total Assets | 527.7M |
| Working Capital | 337.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -209.72M
and capital expenditures 0, giving a free cash flow of -215.59M.
| Operating Cash Flow | -209.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | -215.59M |
| FCF Per Share | -2.27 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
